These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28831737)

  • 1. Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer.
    Ho VKY; Jansen EPM; Wijnhoven BPL; Neelis KJ; van Sandick JW; Verhoeven RHA; Lemmens VEP; van Laarhoven HWM
    Ann Surg Oncol; 2017 Nov; 24(12):3647-3657. PubMed ID: 28831737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a dutch cohort study.
    Stiekema J; Trip AK; Jansen EP; Aarts MJ; Boot H; Cats A; Ponz OB; Gradowska PL; Verheij M; van Sandick JW
    Ann Surg Oncol; 2015 Feb; 22(2):581-8. PubMed ID: 25164039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study.
    Yeh JM; Tramontano AC; Hur C; Schrag D
    Gastric Cancer; 2017 Sep; 20(5):811-824. PubMed ID: 28205057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy.
    In H; Kantor O; Sharpe SM; Baker MS; Talamonti MS; Posner MC
    Ann Surg Oncol; 2016 Jun; 23(6):1956-62. PubMed ID: 26753752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy.
    Kucukoner M; Arpaci E; Isikdogan A; Bilici M; Uncu D; Cetin B; Dane F; Inanc M; Ekinci AS; Inal A; Cayir K; Yetisyigit T; Ozdemir N; Kaplan MA; Aksoy S; Alkıs N; Tekin SB; Eroglu C; Turhal S; Buyukberber S
    Neoplasma; 2013; 60(1):19-25. PubMed ID: 23067212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions.
    Sandler S
    Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy.
    Jácome AA; Wohnrath DR; Scapulatempo Neto C; Fregnani JH; Quinto AL; Oliveira AT; Vazquez VL; Fava G; Martinez EZ; Santos JS
    Gastric Cancer; 2013 Apr; 16(2):233-8. PubMed ID: 22740060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital variation and the impact of postoperative complications on the use of perioperative chemo(radio)therapy in resectable gastric cancer. Results from the Dutch Upper GI Cancer Audit.
    Schouwenburg MG; Busweiler LAD; Beck N; Henneman D; Amodio S; van Berge Henegouwen MI; Cats A; van Hillegersberg R; van Sandick JW; Wijnhoven BPL; Wouters MWJ; Nieuwenhuijzen GAP;
    Eur J Surg Oncol; 2018 Apr; 44(4):532-538. PubMed ID: 29439836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
    Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
    Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
    Stiekema J; Trip AK; Jansen EP; Boot H; Cats A; Ponz OB; Verheij M; van Sandick JW
    Ann Surg Oncol; 2014 Apr; 21(4):1107-14. PubMed ID: 24306660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study.
    Mokadem I; Dijksterhuis WPM; van Putten M; Heuthorst L; de Vos-Geelen JM; Haj Mohammad N; Nieuwenhuijzen GAP; van Laarhoven HWM; Verhoeven RHA
    Gastric Cancer; 2019 Nov; 22(6):1263-1273. PubMed ID: 30949777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemoradiotherapy versus adjuvant chemotherapy for R1 resected gastric cancer: a retrospective cohort study.
    Zhou ML; Li GC; Yang W; Deng WJ; Hu R; Wang Y; Long ZW; Liu XW; Wang YN; Zhang Z
    Br J Radiol; 2018 Sep; 91(1089):20180276. PubMed ID: 29906235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer.
    Morganti AG; Falconi M; van Stiphout RG; Mattiucci GC; Alfieri S; Calvo FA; Dubois JB; Fastner G; Herman JM; Maidment BW; Miller RC; Regine WF; Reni M; Sharma NK; Ippolito E; Valentini V
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):911-7. PubMed ID: 25220717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction.
    Kofoed SC; Muhic A; Baeksgaard L; Jendresen M; Gustafsen J; Holm J; Bardram L; Brandt B; Brenø J; Svendsen LB
    Scand J Surg; 2012; 101(1):26-31. PubMed ID: 22414465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center.
    Costa WL; Coimbra FJ; Fogaroli RC; Ribeiro HS; Diniz AL; Begnami MD; Mello CA; Fanelli MF; Silva MJ; Fregnani JH; Montagnini AL
    Radiat Oncol; 2012 Oct; 7():169. PubMed ID: 23068190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases.
    Inoue T; Yachida S; Usuki H; Kimura T; Hagiike M; Okano K; Suzuki Y
    Ann Surg Oncol; 2012 Sep; 19(9):2937-45. PubMed ID: 22466666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database.
    Tsai C; Mueller A; Maubach J; Warschkow R; Nussbaum DP; Schmied BM; Blazer D; Gloor B; Worni M
    Dig Surg; 2020; 37(3):249-257. PubMed ID: 31340206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.